Darin J. Weber Sells 84,103 Shares of ProKidney Corp. (NASDAQ:PROK) Stock

ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber sold 84,103 shares of ProKidney stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $1.73, for a total transaction of $145,498.19. Following the transaction, the senior vice president now directly owns 189,670 shares of the company’s stock, valued at $328,129.10. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

ProKidney Trading Down 15.5 %

Shares of NASDAQ PROK opened at $2.40 on Friday. ProKidney Corp. has a 1-year low of $1.12 and a 1-year high of $13.51. The company has a market cap of $550.43 million, a PE ratio of -4.21 and a beta of 1.08. The company has a 50-day moving average of $1.59 and a two-hundred day moving average of $1.81.

ProKidney (NASDAQ:PROK) last announced its earnings results on Thursday, March 21st. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. As a group, equities research analysts forecast that ProKidney Corp. will post -0.65 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on PROK shares. Morgan Stanley started coverage on shares of ProKidney in a report on Thursday, March 7th. They set an “equal weight” rating and a $3.00 price target for the company. Bank of America downgraded shares of ProKidney from a “buy” rating to a “neutral” rating in a report on Tuesday, January 2nd.

Institutional Investors Weigh In On ProKidney

Institutional investors and hedge funds have recently modified their holdings of the business. Jump Financial LLC acquired a new stake in ProKidney during the 3rd quarter worth $216,000. SG Americas Securities LLC bought a new stake in ProKidney in the third quarter valued at about $78,000. HRT Financial LP bought a new stake in ProKidney in the first quarter valued at about $730,000. UBS Group AG lifted its stake in ProKidney by 97.5% in the first quarter. UBS Group AG now owns 5,209 shares of the company’s stock valued at $59,000 after buying an additional 2,571 shares during the period. Finally, ExodusPoint Capital Management LP bought a new position in ProKidney during the first quarter worth about $151,000. 51.59% of the stock is owned by institutional investors.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.